

State of Oklahoma SoonerCare Braftovi[®] (Encorafenib) Prior Authorization Form

Member Name:	Date of Birth:	Member ID#:	
	Drug Information		
Pł	narmacy billing (NDC:)	
Dose:	Regimen:	Start Date:	
	Billing Provider Inform		
Provider NPI:	NPI: Provider Name:		
Provider Phone:	Provider Fa	Provider Fax:	
	Prescriber Informat	tion	
Prescriber NPI: Prescriber Name:			
Prescriber Phone:	Prescriber Fax:	Specialty:	
Criteria			
For Initial Authorizati	on:		
1. Please indicate the d	iagnosis and information:		
	e or Metastatic Melanoma		
A. Does member have BRAF V600E or V600K mutation? Yes No			
	rafenib be used in combination with binime		
	Metastatic Colorectal Cancer		
	mber have BRAF V600E mutation? Yes	No	
	rafenib be used in combination with cetuxin		
		within the last 12 months? Yes No	
	ase progressed following metastatic therapy		
		y: 163100	
	 □ Non-Small Cell Lung Cancer (NSCLC) A. Is diagnosis metastatic NSCLC? Yes No 		
•	mber have BRAF V600E mutation? Yes	No	
			
	rafenib be used in combination with binime		
	one of the above, please indicate diagnosis		
Additional information:			
For Continued Autho			
Date of last dose:			
		n encoratenih therany? Ves No	
 Does patient have any evidence of progressive disease while on encorafenib therapy? Yes No Has the member experienced any adverse drug reactions related to encorafenib therapy? Yes No 		· · · · · · · · · · · · · · · · · · ·	
•	verse reactions:	• • • • • • • • • • • • • • • • • • • •	
Prescriber Signature:	<u> </u>	Date:	
_		formation is true and correct to the best of my	
	send in chart notes. Specific information will be		

PLEASE PROVIDE THE INFORMATION REQUESTED AND RETURN TO:

University of Oklahoma College of Pharmacy Pharmacy Management Consultants Product Based Prior Authorization Unit

> Fax: 1-800-224-4014 Phone: 1-800-522-0114 Option 4

CONFIDENTIALITY NOTICE

This document, including any attachments, contains information which is confidential or privileged. If you are not the intended recipient, be aware that any disclosure, copying, distribution, or use of the contents of this information is prohibited. If you have received this document in error, please notify the sender immediately by telephone to arrange for the return of the transmitted documents or to verify their destruction.

Pharm-105 3/5/2024